Krystal Biotech (NASDAQ:KRYS) Sets New 1-Year High – Time to Buy?

Krystal Biotech, Inc. (NASDAQ:KRYS) reached a new 52-week high during trading on Monday . The stock traded as high as $265.92 and last traded at $253.68, with a volume of 180498 shares changing hands. The stock had previously closed at $252.17.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Citigroup lifted their price target on shares of Krystal Biotech from $166.00 to $198.00 and gave the company a “neutral” rating in a research report on Tuesday, November 4th. Weiss Ratings reissued a “hold (c+)” rating on shares of Krystal Biotech in a research report on Monday, December 22nd. Chardan Capital raised their price target on shares of Krystal Biotech from $216.00 to $220.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. HC Wainwright reissued a “buy” rating and issued a $240.00 price objective on shares of Krystal Biotech in a research note on Monday, September 15th. Finally, Bank of America raised their target price on Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a report on Friday, October 17th. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $228.14.

Krystal Biotech Stock Performance

The stock has a market cap of $7.36 billion, a PE ratio of 38.03 and a beta of 0.48. The business has a 50 day moving average price of $215.65 and a two-hundred day moving average price of $174.95.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, November 3rd. The company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $1.54. The company had revenue of $97.80 million for the quarter, compared to analysts’ expectations of $93.72 million. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%. As a group, research analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the completion of the sale, the insider owned 1,413,711 shares in the company, valued at $311,242,613.76. This trade represents a 1.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 13.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Krystal Biotech

Institutional investors and hedge funds have recently bought and sold shares of the company. Edgestream Partners L.P. bought a new position in shares of Krystal Biotech in the second quarter worth $2,705,000. State of New Jersey Common Pension Fund D boosted its stake in Krystal Biotech by 45.2% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 15,033 shares of the company’s stock worth $2,066,000 after purchasing an additional 4,682 shares during the period. Voya Investment Management LLC grew its holdings in Krystal Biotech by 46.7% during the 3rd quarter. Voya Investment Management LLC now owns 93,908 shares of the company’s stock valued at $16,578,000 after buying an additional 29,915 shares in the last quarter. EP Wealth Advisors LLC bought a new stake in shares of Krystal Biotech during the first quarter valued at about $473,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Krystal Biotech by 173.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock valued at $103,764,000 after buying an additional 365,304 shares during the period. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.